Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Buzepide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 10/20 | 0.57 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 4/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.41 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenpiverinium SCHEMBL1650132 | 0.99 | CHRM3 (0.55) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Fenpiverinium SCHEMBL23654 | 0.97 | CHRM3 (0.53) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Fenpiverinium SCHEMBL28086315 | 0.85 | OPRM1 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Iodide SCHEMBL29558329 | 0.78 | CHRM2 (0.83) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL9295790 | 0.72 | CHRM3 (0.59) | CHRM3CHRM2CHRM1KMT2ACTDSP1 | |
| SCHEMBL10524246 | 0.70 | CHRM3 (0.57) | CHRM3CHRM2CHRM1KMT2ACTDSP1 | |
| Fenpipramide SCHEMBL149504 | 0.70 | CHRM2 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL219257 | 0.70 | CHRM2 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Fenpipramide SCHEMBL11716116 | 0.69 | OPRM1 (0.56) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tricyclamol SCHEMBL30573196 | 0.69 | CHRM2 (0.58) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| EP-1986693-A1 | A BASE FORMING DRUG-LAYERED SILICATE HYBRID CONTAINING BASIC POLYMER AND ITS SYNTHESIS METHOD | Nanohybrid Co., Ltd. (KR) | 2008-11-05 | — | — | EP | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080119519-A1 | Base Forming Drug-Layered Silicate Hybrid Containing Basic Polymer and its Synthesis Method | NANOHYBRID CO., LTD. (KR) | 2008-05-22 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006088337-A1 | A BASE FORMING DRUG-LAYERED SILICATE HYBRID CONTAINING BASIC POLYMER AND ITS SYNTHESIS METHOD | NANOHYBRID CO., LTD. (KR) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119519-A1 | Base Forming Drug-Layered Silicate Hybrid Containing Basic Polymer and its Synthesis Method | SLC43A1, SLC7A1, DERA | CHRM3 2784/4885CHRM1 1392/4885CHRM2 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.